Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The optimal care study

Ali T. Taher, Khaled M. Musallam, Mehran Karimi, Amal El-Beshlawy, Khawla Belhoul, Shahina Daar, Mohamed Salaheldin Saned, Abdul Hamid El-Chafic, Maria R. Fasulo, Maria D. Cappellini

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.

Original languageEnglish
Pages (from-to)1886-1892
Number of pages7
JournalBlood
Volume115
Issue number10
DOIs
Publication statusPublished - Mar 11 2010

Fingerprint

beta-Thalassemia
Hydroxyurea
Pulmonary Hypertension
Leg Ulcer
Chelation
Chelation Therapy
Iron
Cholelithiasis
Hypogonadism
Splenectomy
Hypothyroidism
Osteoporosis
Medical problems
Thrombosis
Liver
Heart Failure
Therapeutics
Diabetes Mellitus
Multivariate Analysis
Phenotype

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., ... Cappellini, M. D. (2010). Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The optimal care study. Blood, 115(10), 1886-1892. https://doi.org/10.1182/blood-2009-09-243154

Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity : The optimal care study. / Taher, Ali T.; Musallam, Khaled M.; Karimi, Mehran; El-Beshlawy, Amal; Belhoul, Khawla; Daar, Shahina; Saned, Mohamed Salaheldin; El-Chafic, Abdul Hamid; Fasulo, Maria R.; Cappellini, Maria D.

In: Blood, Vol. 115, No. 10, 11.03.2010, p. 1886-1892.

Research output: Contribution to journalArticle

Taher, AT, Musallam, KM, Karimi, M, El-Beshlawy, A, Belhoul, K, Daar, S, Saned, MS, El-Chafic, AH, Fasulo, MR & Cappellini, MD 2010, 'Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The optimal care study', Blood, vol. 115, no. 10, pp. 1886-1892. https://doi.org/10.1182/blood-2009-09-243154
Taher, Ali T. ; Musallam, Khaled M. ; Karimi, Mehran ; El-Beshlawy, Amal ; Belhoul, Khawla ; Daar, Shahina ; Saned, Mohamed Salaheldin ; El-Chafic, Abdul Hamid ; Fasulo, Maria R. ; Cappellini, Maria D. / Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity : The optimal care study. In: Blood. 2010 ; Vol. 115, No. 10. pp. 1886-1892.
@article{295ae28e71d442f88ee4bca4975c9d92,
title = "Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The optimal care study",
abstract = "Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.",
author = "Taher, {Ali T.} and Musallam, {Khaled M.} and Mehran Karimi and Amal El-Beshlawy and Khawla Belhoul and Shahina Daar and Saned, {Mohamed Salaheldin} and El-Chafic, {Abdul Hamid} and Fasulo, {Maria R.} and Cappellini, {Maria D.}",
year = "2010",
month = "3",
day = "11",
doi = "10.1182/blood-2009-09-243154",
language = "English",
volume = "115",
pages = "1886--1892",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity

T2 - The optimal care study

AU - Taher, Ali T.

AU - Musallam, Khaled M.

AU - Karimi, Mehran

AU - El-Beshlawy, Amal

AU - Belhoul, Khawla

AU - Daar, Shahina

AU - Saned, Mohamed Salaheldin

AU - El-Chafic, Abdul Hamid

AU - Fasulo, Maria R.

AU - Cappellini, Maria D.

PY - 2010/3/11

Y1 - 2010/3/11

N2 - Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.

AB - Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.

UR - http://www.scopus.com/inward/record.url?scp=77950420281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950420281&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-09-243154

DO - 10.1182/blood-2009-09-243154

M3 - Article

C2 - 20032507

AN - SCOPUS:77950420281

VL - 115

SP - 1886

EP - 1892

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -